Biosimilars

• Use of Biosimilar Medications in Oncology
• NCCN Guidelines for the Use of Biosimilars
• Biosimilar and Interchangeable Biologics: More Treatment Choices
• FDA’s Overview of the Regulatory Guidance for the Development and Approval of Biosimilar Products in the US
• Biosimilar Product Information

Bladder Cancer

• Bladder Cancer Treatment (PDQ®)–Health Professional Version
• Immunotherapy for Bladder Cancer – American Cancer Society
• Bladder Cancer – Nation Cancer Institute – For Patients
• Bladder Cancer – Nation Cancer Institute – For Providers

Breast Cancer

• Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
• Breast Cancer Treatment – Patient Information
• National Cancer Institute: Breast (Patient Version)
• National Cancer Institute: Breast (Health Professional Version)
• American Society of Clinical Oncology Breast Cancer Guidelines

Colorectal Cancer (CRC)

• Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update
• American Society of Clinical Oncology Gastrointestinal Cancer Guidelines
• US Preventive Services Task Force Colorectal Cancer: Screening—Final Recommendation Statement
• Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
• NCCN Guidelines for Colon Cancer
• NCCN Guidelines for Rectal Cancer
• Colorectal Cancer Alliance: What are NTRK fusions?
• Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer
• When should we order a next generation sequencing test in a patient with cancer?
• Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
• Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
• Colorectal Cancer Screening: What Are My Options?
• National Cancer Institute: Colorectal Cancer [patient version]
• National Cancer Institute: Colorectal Cancer [health professional version]
• National Cancer Institute: Drugs Approved for Colon and Rectal Cancer

General Hematology/Oncology

• Agency for Healthcare Research and Quality Technology Assessment Program. Role of Liquid Biopsy in Detection and Management of Cancer in the Medicare Population
• ASCO Supportive Care and Treatment Related Issues
• Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion
• Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline
• Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set
• NCCN Clinical Practice Guidelines in Oncology
• NCCN Guidelines for Patients
• Increasing Cancer Screening Rates in Primary Care
• Non-invasive early detection of cancer four years before conventional diagnosis using a blood test
• Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
• CDC Recommended Screening Tests for Cancer
• USPSTF Lung Cancer Screening Recommendations: 2021 Updates
• American Cancer Society Guidelines for the Early Detection of Cancer
• American Cancer Society guideline for diet and physical activity for cancer prevention

Hematologic Malignancies

• Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article
• Proteasome Inhibitors for the Treatment of Multiple Myeloma
• Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics
• Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
• Carfilzomib, dexamethasone, and daratumumab for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
• A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma
• Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients
• Multiple Myeloma Disease Overview
• Multiple Myeloma – Treatment Overview for Patients and Caregivers
• Treatment for Multiple Myeloma – for Health Professionals
• National Cancer Institute: Leukemia (Patient Version)
• National Cancer Institute: Leukemia (Health Professional Version)
• National Cancer Institute: Plasma Cell Neoplasms (Including Multiple Myeloma (Patient Version)
• National Cancer Institute: Plasma Cell Neoplasms (Including Multiple Myeloma (Health Professional Version)
• NCCN CLL Guidelines for Patients
• Leukemia & Lymphoma Society Patient Information Booklets
• American Society of Clinical Oncology Hematologic Malignancies Guidelines
• Multiple Myeloma Research Foundation Patient Resources

Hematologic Malignancies and Disorders: Alpha Thalassemia

• Optimal strategies for carrier screening and prenatal diagnosis of α- and β-thalassemia
• Advances in the management of α -thalassemia major: reasons to be optimistic
• Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study
• Alpha-Thalassemia
• What is Thalassemia?

Hematologic Malignancies and Disorders: B-cell Lymphomas

• Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment
• Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
• NCCN Guidelines for Patients: Mantle Cell Lymphoma
• NCCN Guidelines for Patients: Follicular Lymphoma
• NCCN Guidelines for Patients: DLBCL
• NCCN Clinical Practice Guidelines. B-Cell Lymphomas. Version 5.2022
• American Society of Clinical Oncology Hematologic Malignancies Guidelines
• Leukemia & Lymphoma Society Patient Information Booklets

Hematologic Malignancies and Disorders: Chronic Lymphocytic Leukemia (CLL)

• CLL Guide: Information for Patients and Caregivers
• NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022
• NCCN Guidelines: Chronic Lymphocytic Leukemia for Patients

Hematologic Malignancies and Disorders: Multiple Myeloma

• Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
• Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
• Toxicity management strategies for next-generation novel therapeutics in multiple myeloma
• Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial
• Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy
• KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
• “Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience
• Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma
• The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
• Risk Evaluation and Mitigation Strategy (REMS) Document BLENREP (belantamab mafodotin) REMS Program
• Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
• Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
• Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)

Hematologic Malignancies and Disorders: Myelodysplastic Syndromes (MDS)

• NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022
• Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management
• About Myelodysplastic Syndromes (MDS)
• Myelodysplastic Syndromes
• Treating MDS Toolkit
• The Diagnostic Spectrum of MDS, MDS/MPN, and MF Reference Card
• What is MDS? iPad App

Hemophilia

• World Federation of Hemophilia Guidelines for the Management of Hemophilia
• National Hemophilia Foundation Recommendations for Genotyping for Persons with Hemophilia
• Impact of novel hemophilia therapies around the world
• Centers for Disease Control and Prevention: Hemophilia Homepage
• National Hemophilia Foundation: Hemophilia A
• World Federation of Hemophilia: Guidelines for the Management of Hemophilia, 3rd Edition

Hepatocellular carcinoma

• National Cancer Institute: Liver and Bile Duct Cancers (Patient Version)
• National Cancer Institute: Liver and Bile Duct Cancers (Health Professional Version)

Kidney Cancer

• Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline
• Kidney Cancer – American Cancer Society
• Kidney Cancer – NIH – Patient Resources

Lung Cancer

• American Cancer Society Lung Cancer – Patient Information
• American Cancer Society Questions to Ask About Lung Cancer
• US Preventive Services Task Force Lung Cancer: Screening
• Dr Hatim Husain: NCCN Guidelines Adjust to Meet Lung Cancer Treatment Needs
• Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
• National Cancer Institute: Lung Cancer (Patient Version)
• National Cancer Institute: Lung Cancer (Health Professional Version)
• National Comprehensive Cancer Network (NCCN) Guidelines for Treatment of Cancer by Site
• IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer

Melanoma

• Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial
• Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab
• Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti–PD-1 therapy: MASTERKEY-115
• American Cancer Society: Immunotherapy for Melanoma Skin Cancer
• SITC Patient Resources: Melanoma and Other Skin Cancers
• Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now
• Adjuvant immunotherapy for melanoma patients: progress and opportunities
• Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
• Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
• Educational Review: Clinical Application of Immune Checkpoint Blockade for the Treatment of Melanoma
• Clinical updates in neoadjuvant immunotherapy for melanoma before surgery
• Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field
• The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
• Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
• Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field
• NCI: Oncolytic Virus Enables the Immune System to Attack Tumors Subscribe
• Oncolytic virotherapy: basic principles, recent advances and future directions
• Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment
• Oncolytic viruses in melanoma
• Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study
• Melanoma Research Alliance: T-VEC
• Systemic Therapy for Melanoma: ASCO Guideline Rapid Recommendation Update
• What Screening Tests Are There?
• NCCN Guidelines for Patients: Melanoma
• NCCN Clinical Practice Guidelines in Oncology – Cutaneous Melanoma
• Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
• 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study
• Pathological response and survival with neoadjuvant therapy in melanoma
• The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges
• Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect
• Atezolizumab Prescribing Information
• Cobimetinib Prescribing Information
• Vemurafenib Prescribing Information
• Melanoma Treatment – for health professionals
• Melanoma Risk Assessment Tool
• Combination Therapy: Nivolumab + Ipilimumab
• Immunotherapy for Melanoma Skin Cancer
• Targeted Therapy for Melanoma
• The Skin Cancer Foundation: Skin Cancer 101 for Patients

Ovarian Cancer

• SGO Gynecologic Cancer Resources For Patients And Their Families
• ACOG Ovarian Cancer FAQs
• Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline
• ASCO Guidelines: PARP Inhibitors in the Management of Ovarian Cancer—Rapid Update
• Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline
• Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline
• National Cancer Institute: Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (Patient Version)
• National Cancer Institute: Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (Health Professional Version)

Uveal Melanoma

• Tebentafusp-tebn Prescribing Information
• National Comprehensive Cancer Network, NCCN Guidelines Melanoma: Uveal. Version 2.2021
• Intraocular (Uveal) Melanoma Treatment (PDQ®): Patient Version
• The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019)
• Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
• Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis
• Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
• Quality of Life Concerns in Patients with Uveal Melanoma after Initial Diagnosis